Rallybio Files S-4 for Reverse Merger with Candid Therapeutics, Confirming Extreme Shareholder Dilution and $505.5M Financing

summarizeSummary

Rallybio Corp filed an S-4 registration statement detailing its reverse merger with Candid Therapeutics, which will result in existing Rallybio shareholders owning only 3.65% of the combined company, alongside a $505.5 million concurrent financing.

check_boxKey Events

• Reverse Merger Details

  Rallybio Corp will merge with Candid Therapeutics, Inc., with Candid becoming a wholly-owned subsidiary and the combined entity being renamed Candid Therapeutics, Inc.

• Extreme Shareholder Dilution

  Existing Rallybio shareholders are projected to own approximately 3.65% of the combined company on a fully diluted basis, based on a Rallybio valuation of $47.5 million.

• Substantial Concurrent Financing

  The merger is accompanied by a $505.5 million concurrent financing, with investors expected to own 38.80% of the combined company.

• Contingent Value Rights (CVRs)

  Rallybio shareholders will receive CVRs tied to net proceeds from the disposition of Rallybio's legacy assets, including RLYB116 and proceeds from the REV102 sale.

auto_awesomeAnalysis

This S-4 filing provides comprehensive details for the previously announced reverse merger with Candid Therapeutics, a highly dilutive transaction for existing Rallybio shareholders. The merger will see Rallybio effectively acquired by Candid, with Rallybio shareholders retaining a minimal ownership stake of 3.65% in the combined entity, which will be renamed Candid Therapeutics, Inc. The transaction includes a substantial $505.5 million concurrent financing, critical for the combined company's future operations. While the financing provides a lifeline, the extreme dilution and loss of corporate identity represent a significant negative shift for current Rallybio investors. The filing also outlines a proposed reverse stock split and an increase in authorized shares, further underscoring the transformative nature of this event.